Advances in Molecular Pathology – In this article, the authors discuss existing data and ongoing efforts to generate evidence in support of genotype-guided therapy approaches and reimbursement for pharmacogenomic testing.
Pharmacogenetics and Genomics — Hypertension and chronic kidney disease are inextricably linked. Hypertension is a well-recognized contributor to chronic kidney disease progression and, in turn, renal disease potentiates hypertension.
Qualitative Report – This study’s purpose was to develop a typology of subgroups of patients who share common patterns of medication exposure. To create the typology, we used an exemplar sample of 30 patients in a large public healthcare system who had been prescribed the pharmacogenetically actionable opioids codeine or tramadol.
Journal of Personalized Medicine – To understand potential barriers and provider attitudes, we surveyed 285 physicians from five Implementing GeNomics In pracTicE (IGNITE) sites about their perceptions as to the clinical utility of genetic data as well as their preparedness to integrate it into practice.
American Journal of Health-System Pharmacy – This review summarizes requisite pharmacist competencies, educational standards, and the current state of pharmacogenomics education to propose best practice solutions for educators to meet the specific needs and challenges of this complex topic.
Expert Review of Clinical Pharmacology – The present manuscript provides an overview of genetic factors associated with response profiles to platelet P2Y12 receptor inhibitors and their clinical implications, as well as the most recent developments and future considerations on the role of genetic testing in patients undergoing PCI.
BMC Medical Genomics – The objective of this study was to synthesize data on challenges identified by six diverse projects that are part of a National Human Genome Research Institute (NHGRI)-funded network focused on implementing genomics into practice and strategies to overcome these challenges.
Pharmacogenomics – We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.
Personalized Medicine – The objective of this research was to assess medical student preparedness for the use of personalized medicine.
Clinical Pharmacology & Therapeutics – To facilitate multiethnic algorithm-guided warfarin dosing using preemptive genetic testing, we developed a strategy that accounts for the complexity of race and leverages electronic health records for algorithm variables and deploying point-of-care dose recommendations.